CME: Diabetic Retinopathy from Trials to Treatment (Web)

Question Title

* 1. Which of the following technologies was instrumental in defining an ischemic index, a leakage index, and a microaneurysm count in a study by Ehlers and colleagues?

Question Title

* 2. Which of the following studies will evaluate the impact of peripheral lesions and ultra widefield imaging on the risk of diabetic retinopathy progression?

Question Title

* 3. According to DRCR Protocol T, which of the anti-VEGF agents had a slight advantage at 2 years in patients who started treatment with visual acuity of 20/50 or worse?

Question Title

* 4. What is the accepted definition of suboptimal response to anti-VEGF therapy in the retina community?

Question Title

* 5. Which intravitreal steroid has been shown to be most durable?

Question Title

* 6. During Protocol S, how many injections did most eyes receive in 5 years?

Question Title

* 7. Which of the following therapies is being studied in Protocol W for preventing PDR or center-involving DME in eyes at high risk for these complications?

Question Title

* 8. In the PANORAMA study of moderately severe to severe NPDR, what percentage of all eyes treated with aflibercept showed a 2-step improvement in DRSS from baseline?

Question Title

* 9. Please provide your email address

T